Bank of Nova Scotia
NKTR icon

Bank of Nova Scotia’s Nektar Therapeutics NKTR Stock Holding History

Bank of Nova Scotia’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,998
Closed -$546K – 960
2019
Q3 		$546K Buy
1,998
+251
+14% +$92.1K ﹤0.01% 800
2019
Q2 		$932K Sell
1,747
-142
-8% -$71.2K ﹤0.01% 716
2019
Q1 		$952K Sell
1,889
-277
-13% -$164K ﹤0.01% 718
2018
Q4 		$1.07M Sell
2,166
-146
-6% -$88.1K 0.01% 687
2018
Q3 		$2.11M Buy
2,312
+1,137
+97% +$970K 0.01% 633
2018
Q2 		$860K Sell
1,175
-195
-14% -$225K ﹤0.01% 700
2018
Q1 		$2.18M Buy
+1,370
New +$1.76M 0.01% 542

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Bank of Nova Scotia's NKTR Position: Q4 2019 in Review

Bank of Nova Scotia sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 1,998 shares — an estimated $546K sold.

Bank of Nova Scotia first reported a position in NKTR in Q1 2018 and held it in 7 quarters. The position peaked at $2.18M in Q1 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Bank of Nova Scotia reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Bank of Nova Scotia sold 1,998 Nektar Therapeutics shares in Q4 2019, an estimated $546K.
  • Bank of Nova Scotia first reported a position in Nektar Therapeutics in Q1 2018 and held it in 7 quarters.
  • Bank of Nova Scotia's Nektar Therapeutics position peaked at $2.18M in Q1 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Bank of Nova Scotia's 13F filing for Q4 2019, filed 13 Feb 2020.